Linked Life Data

19647219

Source:http://linkedlifedata.com/resource/pubmed/id/19647219

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-8-3
pubmed:abstractText
Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in the development of effective anticancer drugs. A recent report in the New England Journal of Medicine on the early clinical evaluation of Olaparib in cancers lacking the BRCA1 or BRCA2 genes exemplifies this promising new trend.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1878-3686
pubmed:author
pubmed:issnType
Electronic
pubmed:day
4
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
89-90
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
pubmed:affiliation
The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK. arv22@cam.ac.uk
pubmed:publicationType
Journal Article